XGN - Exagen Inc
IEX Last Trade
2.96
-0.030 -1.014%
Share volume: 19,413
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.99
-0.03
-1.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-11-21 | 2022-11-21 | 2023-03-20 | 2023-05-15 | 2023-08-07 | 2023-11-13 | 2024-03-18 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 106.849 M | 101.597 M | 86.221 M | 79.234 M | 64.178 M | 60.928 M | 56.944 M | 50.808 M | |
| Current Assets | 88.164 M | 82.060 M | 72.611 M | 65.716 M | 51.271 M | 48.908 M | 47.841 M | 42.400 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.062 M | 2.717 M | 4.143 M | 4.229 M | 3.570 M | 3.416 M | 4.797 M | 4.232 M | |
| Short Term Investments | 3.062 M | 2.717 M | 4.143 M | 4.229 M | 3.570 M | 3.416 M | 4.797 M | 4.232 M | |
| Total Receivables | 8.715 M | 10.639 M | 6.077 M | 9.303 M | 16.235 M | 17.044 M | 6.551 M | 10.901 M | |
| Current Cash | 76.387 M | 68.704 M | 62.391 M | 52.184 M | 31.466 M | 28.448 M | 36.493 M | 27.267 M | |
| Total Non-current Assets | 18.685 M | 19.537 M | 13.610 M | 13.518 M | 12.907 M | 12.020 M | 9.103 M | 8.408 M | |
| Property Plant Equipment | 7.216 M | 8.331 M | 8.197 M | 8.264 M | 7.875 M | 7.214 M | 5.201 M | 4.775 M | |
| Other Assets | 5.963 M | 5.700 M | 5.413 M | 5.254 M | 5.032 M | 4.806 M | 3.902 M | 3.633 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 5.506 M | 5.506 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 106.849 M | 101.597 M | 86.221 M | 79.234 M | 64.178 M | 60.928 M | 56.944 M | 50.808 M | |
| Total liabilities | 44.025 M | 45.411 M | 43.761 M | 43.297 M | 32.276 M | 33.424 M | 34.250 M | 30.817 M | |
| Total current liabilities | 10.054 M | 11.332 M | 9.623 M | 9.268 M | 8.603 M | 10.119 M | 11.902 M | 8.783 M | |
| Accounts Payable | 3.105 M | 3.669 M | 3.046 M | 1.878 M | 1.309 M | 1.657 M | 3.131 M | 1.470 M | |
| Other liabilities | 810.000 K | 999.000 K | 867.000 K | 726.000 K | 597.000 K | 484.000 K | 357.000 K | 268.000 K | |
| Current long term debt | 979.000 K | 1.009 M | 1.230 M | 1.326 M | 1.361 M | 1.399 M | 1.240 M | 1.273 M | |
| Long term debt | 32.855 M | 32.774 M | 33.271 M | 33.303 M | 23.076 M | 22.821 M | 21.991 M | 21.766 M | |
| Other liabilities | 810.000 K | 999.000 K | 867.000 K | 726.000 K | 597.000 K | 484.000 K | 357.000 K | 268.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 62.824 M | 56.186 M | 42.460 M | 35.937 M | 31.902 M | 27.504 M | 22.694 M | 19.991 M | |
| Common stock | 17.059 M | 17.081 M | 17.198 M | 17.527 M | 17.655 M | 17.693 M | 17.843 M | 17.944 M | |
| Retained earnings | -233.077 M | -241.173 M | -255.527 M | -263.215 M | -268.228 M | -273.643 M | -279.216 M | -282.576 M |